Engineered Doxorubicin Delivery System Using Proteinoid-Poly (L-Lactic Acid) Polymeric Nanoparticles of Narrow Size Distribution and High Molecular Weight for Cancer Treatment

Stella Kiel¹, Michal Kolitz-Domb¹, Enav Corem-Salkmon, Igor Grinberg and Shlomo Margel*

¹These authors contributed equally to this study

The Institute of Nanotechnology and Advanced Materials, Department of Chemistry, Bar-Ilan University, Ramat-Gan, 52900, Israel

Abstract
Doxorubicin (Dox), a widely used anti-cancer drug, was encapsulated within new special-tailored proteinoid nanoparticles (NPs), with the intention to overcome side effects while keeping the drug potency. The synthesis and characterization of four newly-made proteinoids of very high molecular weights (122-149 kDa) and low polydispersity (1.01-1.03) is presented. The proteinoids were synthesized from L-lysine, L-arginine, L-histidine, L-phenylalanine and poly-L-lactic acid (PLLA) segments, and are named P(KRHF-PLLA). Using this selection of amino acids provides basic positive-charged novel tailored proteinoids, with a rigid and biodegradable backbone, achieved by the incorporation of PLLA. The proteinoids self-assemble to yield NPs of a narrow-size distribution. This self-assembly procedure was utilized to encapsulate Dox within the NP core. The optimal Dox-encapsulated NPs were chosen by a study of their size, size distribution and Dox content. The chosen NPs, 15% Dox-loaded P(KRHF-PLLA) NPs were checked for their stability in different conditions. In order to improve tumor uptake and time of circulation in the blood, the chosen NPs were further PEGylated and the effects of PEGylation of the NPs, as well as the effect of the environment, on the release rate of Dox from the NPs were investigated. Additionally, the cytotoxicity of the PEGylated and non-PEGylated Dox-containing NPs was studied by XTT assay and their generation of immune-response was investigated by cytokines induction assay. Overall, the Dox-loaded NPs were found stable, non-immunogenic and showed good cell toxicity, making them good candidates to be used against cancer, while PEGylation improved all parameters.

Keywords: Proteinoid nanoparticles; self-assembly; doxorubicin; drug delivery; cancer treatment.

List of abbreviations

| Abbreviation | Description |
|--------------|-------------|
| a.u.         | Arbitrary units |
| Arg          | Arginine |
| cm           | Centimeter |
| Da, kDa      | Dalton, kilodalton |
| Dox          | Doxorubicin |
| DLS          | Dynamic light scattering |
| DSC          | Differential scanning calorimetry |
| ELISA        | Enzyme linked immunosorbent assay |
| EPR          | Enhanced permeability and retention |
| FTIR, IR     | Fourier transform infrared |
| g            | gram |
| GPC          | Gel permeation chromatography |
| h            | Hour |
| His          | Histidine |
| HPLC         | High performance liquid chromatography |
| HSA          | Human serum albumin |
| J            | Joule |
| LPS, L6529   | Lipopolysacharides |
| Lys          | Lysine |
| M            | Molar |
| mg           | Milligram |
| min          | Minute |
| mL           | Milliliter |
| Mn           | Number average molecular mass |
| Mp           | Molecular mass at the peak |
| Mw           | Weight average molecular mass |
| MWCO         | Molecular weight cut-off |
| N            | Normal |
Introduction

Doxorubicin hydrochloride (Dox) is a cytotoxic anthracycline antibiotic which intercalates with the DNA and is commonly used in the treatment of a wide range of cancers, including different types of carcinomas, hematomal malignancies, and soft-tissue sarcomas [1,2]. Although it is widely used, its use in chemotherapy has been limited, mainly due to severe side effects, including cardiotoxicity and nephrotoxicity [1-5]. Many research labs have been struggling with the need to avoid and overcome the Dox side effects, without reducing the drug potency, usually by developing nanosized biospecific drug carriers [1, 3, 6, 7]. The most important requirement for potential drug carriers is a combination of a high drug loading capacity and a long bloodstream circulation time [8]. Typically, using polyethylene glycol (PEG) grafting on the outer surfaces of the drug carriers prevents non-specific binding of serum proteins, and promotes escape from phagocytosis [9,10]. The nanometric size of these drug carriers allows their accumulation in tumors through the enhanced permeability and retention (EPR) effect [6]. One example of a nanosized drug carrier system of the Dox is Doxil, a liposomal formulation containing 12.5% Dox, which decreases its cardiotoxicity [11]. It was first to be approved in 1995 for the treatment of solid tumors [12,13]. Doxil consists of a PEG-lipid surface which guarantees prolonged circulation and improves the tumor uptake [14].

Proteinoids, polymers made of amino acids by thermal condensation polymerization, are unique synthetic polymers discovered by Fox and coworkers [15-17]. Natural or synthetic amino acids are polymerized by step-growth polymerization in a special procedure, which is initiated by heating the amino acids to melting. The polymerization takes place at a high temperature, 140-180 °C, in an inert atmosphere in absence of additives such as solvents or catalysts [16-21]. The accepted mechanism of this polymerization process is based on the role of lysine as a solvent for the other monomers, as it is condensed into the caprolactam under the high temperature conditions. The caprolactam initiates the polymerization with the rest of the present amino acids [15-17, 22]. A brief schematic description of the polymerization process is shown in Figure 1.

![Figure 1: Preparation scheme of proteinoids by thermal polymerization of amino acids.](image1)

The proteinoids previously reported were of low molecular weights, up to approximately 10 kDa [16-19]. Post polymerization, the proteinoid may form micro- or nano-sized particles through a self-assembly procedure [23]. Briefly, the proteinoid is heated in aqueous conditions to dissolution and then slowly cooled to room temperature, leading to self-assembly into hollow nanoparticles [23]. If a suitable molecule is present during the particle formation, encapsulation of this molecule within the particle will occur [24], as presented in Figure 2.

![Figure 2: Schematic representation of the self-assembly of proteinoid particles; “hydrophobic moieties are represented by...](image2)
Amino acid content (weight % of total monomer)

| Polymer            | L-Lys(K) | L-Arg(R) | L-His(H) | L-Phe(F) | PLLA (2 kDa) |
|--------------------|----------|----------|----------|----------|-------------|
| P(KRHF-PLLA) 20:30 | 25       | 15       | 20       | 25       | 10          |
| P(KRHF-PLLA) 25:25 | 25       | 15       | 20       | 25       | 10          |
| P(KRHF-PLLA) 30:20 | 25       | 15       | 20       | 25       | 10          |

*Polymer made of lysine (K), arginine (R), histidine (H), phenylalanine (F) and PLLA; numbers represent the varied percentages of histidine and phenylalanine, respectively, as the percentages of lysine, arginine and PLLA remain constant, 25%, 15% and 10%, respectively.

Materials and Methods

The following analytical-grade chemicals were purchased from commercial sources and used without further purification: L-lysine, L-arginine, L-histidine, L-phenylalanine, sodium chloride, sodium hydroxide 1N, hydrochloric acid 1N, Ficoll, lipopolysaccharides (LPS, L6529), Toll-like receptor 4 (TLR4), human serum albumin (HSA) and bovine plasma fibrinogen (340 kDa), using super-pure HPLC water though a linear BioSep SEC-s3000 column (Phenomenex, CA, USA) at a flow rate of 1 mL/min, 80 °C. The molecular weights were determined relative to PEG standards (Polymer Standards Service, Silver Spring, MD, USA) with a molecular weight range of 100-450000 Da, human serum albumin (HSA, 67 kDa) and bovine plasma fibrinogen (340 kDa), using Clarity chromatography software (DataApex, Prague, Czech Republic). The optical activities of the proteinoids were determined using a PE 343 polarimeter (Perkin Elmer, MA, USA). All measurements were done in water, at 589 nm at 25 °C. The thermal behavior of the proteinoids, hollow, and Dox-loaded NPs was de-

Preparation of Hollow and Dox-loaded Proteinoid Nanoparticles

Proteinoid particles were prepared via a self-assembly process as previously described by our research group [29]. Briefly, 50 mg of the dried proteinoid were added to 5 mL of 10-5 N NaCl solution. The mixture was then kept at 80 °C for 30 min to complete the dissolution of the proteinoid. Particle formation was achieved by removal of the heating, as the mixture was left to cool to room temperature. The Dox-loaded proteinoid NPs were obtained by the addition of Dox to the hot solution, prior to particle formation by self-assembly. Varying amounts (0, 10, 15, 25 and 30 weight % relative to the proteinoid) of Dox were dissolved in 0.5 mL of 10-5 N NaCl solution and added to the heated solution of proteinoid (50 mg in 4.5 mL) to give a total volume of 5 mL. The excess drug was removed by extensive dialysis against super-purified water (10 kDa MWCO).

Proteinoid and NPs Analysis

The molecular weights and polydispersity indices of the dried crude proteinoids were determined using Gel Permeation Chromatography (GPC) consisting of a Waters Spectra Series P100 isocratic HPLC pump with an ERMA ERC-7510 refractive index detector and a Rheodyne (Cotati, CA, USA) injection valve with a 20 μL loop (Waters, MA, USA). The samples were eluted with super-pure HPLC water though a linear BioSep SEC-s3000 column (Phenomenex, CA, USA) at a flow rate of 1 mL/min, 80 °C. The molecular weights were determined relative to PEG standards (Polymer Standards Service, Silver Spring, MD, USA) with a molecular weight range of 100-450000 Da, human serum albumin (HSA, 67 kDa) and bovine plasma fibrinogen (340 kDa), using Clarity chromatography software (DataApex, Prague, Czech Republic). The optical activities of the proteinoids were determined using a PE 343 polarimeter (Perkin Elmer, MA, USA). All measurements were done in water, at 589 nm at 25 °C. The thermal behavior of the proteinoids, hollow, and Dox-loaded NPs was de-

Preparation of Proteinoid Nanoparticles

Preparation of Proteinoid Nanoparticles: PLLA (2 kDa) was incorporated within the proteinoids to achieve enhanced biodegradability. The lysine-based proteinoids were used to encapsulate Dox to create anti-cancer nanoparticles (NPs) that can specifically detect and treat cancerous tumors. The Dox-loaded proteinoid NPs were studied in terms of size and size distribution, stability, cytotoxicity, drug release over time and immunogenicity.

In the present study, several types of new proteinoids of high molecular weights and low polydispersity were synthesized from the natural amino acids lysine, arginine, histidine and phenylalanine in order to obtain new lysine-based proteinoids. PLLA was incorporated within the proteinoids to achieve enhanced biodegradability. The lysine-based proteinoids were used to encapsulate Dox to create anti-cancer nanoparticles (NPs) that can specifically detect and treat cancerous tumors. The Dox-loaded proteinoid NPs were studied in terms of size and size distribution, stability, cytotoxicity, drug release over time and immunogenicity.
super-purified water was spread on a glass surface, and then dried (Japan). For this purpose, a drop of dilute particle dispersion in SEM. SEM pictures were obtained with a JEOL, JSM-840 Model (Sympatec GmbH, Germany). Dried particle size and size temperature with a particle DLS analyzer model Nanophox dispersed in super-purified water were measured at room

The hydrodynamic diameter and size distribution of the particles NP dispersions, weight of NPs is taken after lyophilization.

2) Nanoparticle yield (%) = \frac{ weight of NPs }{ weight of proteinoid + drug fed initially } \times 100%

where weight of drug in NPs is calculated from the absorbance of NP dispersions, weight of NPs is taken after lyophilization.

The absorbance spectra of free Dox and Dox-loaded NPs were recorded in a pH 2 buffer and physiological pH (7.4), at 400-600 nm. The total concentration of free Dox and Dox-loaded NPs was 1 mg/mL. Absorbance spectra were obtained using a Cary 100 UV-Visible spectrophotometer (Agilent Technologies Inc., CA, USA).

The Dox loading content was determined by the following method: Dox-loaded NPs were lyophilized and then disrupted by an addition of a pH 2 buffer and sonication. The samples were analyzed by their absorbance spectra at 487 nm. Quantification was performed using a calibration curve of Dox standard solutions of known concentrations (0-125 µg/mL) in a pH 2 buffer at 487 nm (R² = 0.999). Each experiment was carried out in triplicate, and the average values were compared.

NP formation yield and drug entrapment efficiency were calculated using Equations (1) and (2), respectively:

1) Nanoparticle yield (%) = \frac{ Weight of NPs }{ weight of proteinoid + drug fed initially } \times 100%

2) Nanoparticle yield (%) = \frac{ weight of NPs }{ weight of drug fed initially } \times 100%

PEGylation of the Dox-loaded Proteinoid NPs

PEGylated Dox-loaded proteinoid NPs were prepared by an initial reaction of the primary amine groups on the surface of the proteinoid NPs with NHS-PEG-maleimide. Briefly, NHS-PEG-maleimide (20 mg) was dissolved in PBS (1 mL). 500 µL of the NHS-PEG-maleimide solution was then added to 2 mL of Dox-loaded NPs (10 mg/mL in PBS) and the reaction was stirred for 1 h at room temperature. The obtained PEGylated Dox-loaded NPs, named PEG-Dox-loaded NPs, were then washed from excess reagents by extensive dialysis against super-purified water. Following dialysis, 10% v/v of 1M bicarbonate buffer was added to the PEG-Dox-loaded NPs. Blocking of residual amine groups was then accomplished by adding 50 mg of glycine to the PEG-Dox-loaded NP aqueous dispersion. Hollow proteinoid NPs were also PEGylated by the same procedure. The PEGylated NPs were characterized by DLS for their size and size distribution as described above.

In vitro Drug Release Study

In vitro release of Dox from Dox-loaded NPs and PEG-Dox-loaded NPs was carried out under sink conditions (drug concentration in the medium was kept five times lower than the saturation solubility of Dox in buffer). Particle samples were suspended in PBS to give a final concentration of 0.5 mg/mL. NP suspensions in PBS, human serum and human blood were prepared to a final concentration of 20% NPs v/v. All the samples were placed in a shaker with a constant agitation at 37 °C. Periodically, the samples were filtered through a centrifugation tube (Vivaspin 30 kDa MWCO) and supernatant samples were taken at each time point. The concentration of released Dox in each sample was determined by the absorbance at 487 nm, taking the initial concentration of Dox within the NPs as an absolute value. Dox concentrations were determined using a calibration curve of known Dox concentrations, as described above. The study was performed in sample triplicates.

Cell Proliferation Analysis by XTT

In vitro toxicity of hollow NPs, non-PEGylated and PEGylated Dox-loaded NPs was tested using an XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5 carboxanilide salt) assay on A172 human glioblastoma cells, HCT116 human colon
carcinoma and MDA-MB-231 human invasive ductal carcinoma. The cells were treated with hollow NPs and Dox-loaded NPs, both PEGylated and non-PEGylated. Treatment with Dox-containing NPs, PEGylated and non-PEGylated, was done at two concentrations: 0.01 and 0.05 mg/mL with 1.66 µg and 8.3 µg Dox, respectively. Hollow PEGylated and non-PEGylated NP treatment was done only with the higher concentration of 0.05 mg/mL. Cells treated with an equivalent amount of free Dox and untreated cells served as control groups. Human glioblastoma cells were seeded in a 96 well-plate at a density of 1x10⁶ cells/well with 100 µL culture medium and grown in a humidified 5% CO₂ atmosphere at 37 °C before the addition of the samples. Next, Dox-loaded NP samples dispensed in the culture medium were added to a 96-well-plate, giving a final concentration of 0.01 mg/mL and 0.05 mg/mL of NPs per well. After incubation for 48 h at 37 °C, the 50 µL XTT solution was added to each well according to the kit manufacturer instructions. The percentage of cell cytotoxicity was calculated as shown in the manufacturer protocol for the XTT toxicity detection kit [30]. All samples were tested in sixfold.

Cytokines Induction Assay

The secretion levels of three different inflammatory interleukins were tested using IL-6 and TNF-α as a model for the innate immune response and IL-10 as a model for the late immune response. Cytokines induction assay was performed according to literature [31].

The effect of Dox-loaded NPs, in the presence or absence of bound PEG, on TNF-α, IL-10 and IL-6 cytokines secretion from human Peripheral Blood Mononuclear Cells (PBMCs) was tested. PBMCs were freshly isolated from the blood of 3 healthy human donors obtained from Tel Hashomer (Sheba) blood bank. Whole blood of each human was diluted with PBS/-/ in a volume ratio of 1:1. Samples containing 4 mL of diluted blood were then gently overlaid onto 3 mL Ficoll (3:4 ratio). A gradient was then obtained by centrifugation at 22 °C, 1400 rpm for 35 min. Opaque-light PBMCs ring was removed from the interphase into a new tube. The cells were then centrifuged at 22 °C, 1400 rpm for 10 min. Each PBMC pellet was resuspended in a PBMC growth medium (with 5% fetal bovine serum and 1% penicillin/streptomycin solution) to which PBS dispersions of either the Dox-loaded NPs or PEG-Dox-loaded NPs were added. The final concentration of each 1 mL well (24 well-plates) contained 3 x 10⁶ cells and 0.05 mg NPs. LPS was used as a positive control (100 ng/mL) and PBS/-/ as a negative control. The different 24 well-plates were then incubated at 37 °C humidified, 5% CO₂ for 2 and 24 h. Upon incubation, at each time interval, the cells were centrifuged at 1400 rpm for 10 min and the supernatant was removed and stored in -80 °C freezer for further quantification of secreted cytokines. Human cytokines TNF-α, IL-10 and IL-6 levels were determined using human IL-6, IL-10 and TNF-α ELISA kits according to the manufacturer instructions.

Results and Discussion

Preparation of Proteinoids by Thermal Condensation Polymerization

All the polymers were produced via a simple thermal condensation reaction which utilizes the carboxylate and amine groups of an amino acid side chain or those at the α-position [32]. To obtain a product with good yield by a thermal condensation reaction, anhydrous conditions and inert atmosphere are required [33]. Lysine plays the main role in this process. It promotes the initiation of the polymerization and determines the basic nature of the resulting proteinoids [34]. Histidine was chosen for its imidazole group which can facilitate a proton influx, known as the proton sponge effect, to endosomes, leading to endosomal/lysosomal escape [35]. Also, it is well known that the interaction of a guanidinium-head group of arginine with membrane phospholipids enhances membrane permeability [36]. The combination of histidine and arginine motives in the proteinoids can both promote endosomal escape and increase the efficiency of internalization though the endocytic pathway [37,38].

Four different basic-nature proteinoids were obtained using thermal condensation polymerization. To evaluate the different nature of various proteinoid compositions, the percentages of histidine and phenylalanine were varied from 35% and 15% in P(KRHF-PLLA) 35:15 to 20% and 30% in P(KRHF-PLLA) 20:30, respectively, whereas the composition of lysine, arginine, and P(φ)LLA was kept constant, as presented in Table 1.

Table 2 depicts the molecular weights, polydispersity indices (PDI), and optical activity measurements of the obtained proteinoids. The thermal condensation polymerization that yields proteinoids is a random process and as such is known to yield low molecular weight polymers with high polydispersity [39,40]. The presented method surprisingly allows to synthesize polymers with a very low PDI and relatively high molecular weights using thermal polycondensation by maintaining certain reaction conditions [23, 24]. As can be seen in the table, all polymers have high molecular weights, ranging from 122 to 149 kDa. Also, as mentioned previously, the PDIs of the polymers are very low, at the range of 1.01-1.03. It should be noted that the 2 kDa P(φ)LLA is fully polymerized within the proteinoid backbone, as no corresponding peak was observed. Although they undergo a high temperature procedure which causes transitions, overall, the proteinoids remain optically active. This may become useful in many biological applications [23].

Table 2: Mw, Mn, Mp, polydispersity and optical activity of the various proteinoids.

| Proteinoid | Mw (Da) | Mn (Da) | Mp (Da) | PDI | Optical Activity [α] 25 °C c=1 (~) |
|------------|---------|---------|---------|-----|----------------------------------|
| P(KRHF-PLLA) 35:15 | 133400 | 129600 | 129200 | 1.03 | -4.2 |
| P(KRHF-PLLA) 30:20 | 122400 | 121400 | 123800 | 1.01 | -34.2 |
| P(KRHF-PLLA) 25:25 | 140800 | 139400 | 136900 | 1.01 | -27.8 |
| P(KRHF-PLLA) 20:30 | 149300 | 146000 | 142400 | 1.02 | -65.6 |

The proteinoids were prepared according to the experimental section; molecular masses were measured byGPC; Mp is the molecular mass at the peak; PDI is the polydispersity index, given by Mw/Mn; specific optical rotation (α=1, in H₂O, at 25 °C).

Table 3 presents the thermal properties of the proteinoids investigated by DSC and TGA, as described above. The melting temperatures of the different proteinoids varied at 295-337 °C. As can be noticed, the range of temperatures is not wide, and the reason lies in their monomeric composition. While decreasing the ratio of histidine to phenylalanine from 35:15 to 20:30, the melting temperatures of the different proteinoids varied at 295-337 °C.
TGA measurements of the proteinoids depict a similar pattern in the decomposition temperatures. These temperatures vary from 339 °C up to 426 °C. The weight loss at 400 °C of all proteinoids was in the range of 46-52%. P (KRHF-PLLA) 20:30, with 30% phenylalanine, has the highest decomposition temperature of 426 °C, and it lost 46% of the initial weight at 400 °C. This can be explained by its increased rigidity, caused by the increased relative amount of phenylalanine.

Table 3: Thermal properties of proteinoids produced by thermal polymerization.

| Proteinoid         | $T_d$ (°C) | $\Delta H_m$ (J/g) | Weight loss (%) | $T_{dec}$ (°C) |
|--------------------|------------|--------------------|-----------------|----------------|
| P(KRHF-PLLA) 35:15 | 295        | -270               | 52              | 339            |
| P(KRHF-PLLA) 30:20 | 302        | -447               | 48              | 355            |
| P(KRHF-PLLA) 25:25 | 308        | -513               | 47              | 362            |
| P(KRHF-PLLA) 20:30 | 337        | -567               | 46              | 426            |

$T_d$ and $\Delta H_m$ were measured by DSC; weight loss was measured by TGA at 400 °C; $T_{dec}$ (temperature of decomposition) was measured by TGA/DSC and refers to the exothermal peak in DSC.

Preparation of Hollow and Dox-loaded Proteinoid Nanoparticles

As described above, the hollow and Dox-loaded proteinoid NPs were formed by a self-assembly mechanism. All proteinoids self-assembled to obtain hollow proteinoid NPs, as well as 15% Dox-loaded NPs, by the procedure described above. In order to select the best candidate for further research, size and ζ-potential measurements were performed. Table 4 summarizes the sizes and ζ-potentials of the hollow and Dox-loaded proteinoid NPs. As can be seen in the table, the smallest hollow and Dox-loaded particles were synthesized using P(KRHF-PLLA) 20:30. The Dox-loaded particles formed from the same proteinoid also had the highest ζ-potential, 16.6 Mv, which makes them the most stable due to their low tendency to aggregate in aqueous media.

Table 4: Characteristics of hollow and 15% Dox-loaded proteinoid NPs.

| Proteinoid         | Size of hollow NPs (nm) | Size of Dox-loaded NPs (nm) | ζ-potential (mV) of Dox-loaded NPs |
|--------------------|-------------------------|-----------------------------|-----------------------------------|
| P(KRHF-PLLA) 35:15 | 226.7 ± 41.9            | 100.3 ± 38.7                | 8.8                               |
| P(KRHF-PLLA) 30:20 | 32.1 ± 5.7              | 302.2 ± 31.8                | 8.1                               |
| P(KRHF-PLLA) 25:25 | 278.5 ± 30.5            | 193.4 ± 31.6                | 10.1                              |
| P(KRHF-PLLA) 20:30 | 36.2 ± 6.9              | 111.5 ± 15.2                | 16.6                              |

*Particle size and size distribution of hollow NPs and the Dox-loaded NPs were measured by DLS; ζ-potential of Dox-loaded NPs was measured by a ζ-potential analyzer at a concentration of 10 mg/mL and pH of 7.4.

In order to optimize the loaded Dox concentration, P(KRHF-PLLA) 20:30 Dox-loaded NPs with varied initial Dox concentration were analyzed to estimate their size and the Dox entrapment efficiency within the NPs. Table 5 shows that generally, as the Dox concentration increases, the size of the NPs increases.

The optimal entrapment efficiency of 93 ± 12% was achieved by using an initial Dox concentration of 15%. The size of hollow P (KRHF-PLLA) 20:30 NPs was 36.2 ± 6.9 nm, while the size of the Dox-loaded NPs was 111.5 ± 15.2 nm. Based on the presented data, 15% Dox-loaded P(KRHF-PLLA) 20:30 NPs were chosen as the optimal NPs for further research. This result competes with the Dox concentration in the commercial drug Doxil, in which 12.5% was an optimum [12]. Rising above this concentration, higher entrapment efficiency was not achieved.

Table 5: Characteristics of Dox-loaded P(KRHF-PLLA) 20:30 NPs.

| Drug fed initially (%) | NP formation yield (%) | Entrapment efficiency (%) | Size of NPs (nm) |
|------------------------|------------------------|---------------------------|-----------------|
| 10                     | 99                     | 73 ± 11                   | 96.5 ± 16.1     |
| 15                     | 97                     | 93 ± 12                   | 111.5 ± 15.2    |
| 25                     | 94                     | 87 ± 11                   | 116.7 ± 2.0     |
| 30                     | 98                     | 85 ± 14                   | 880.8 ± 475.4   |

*Initial drug concentration that was put in the self-assembly reaction vessel; †percentages of NP formation and entrapment are calculated as described in section 2.4; ‡particle size and size distribution of hollow NPs and the Dox-loaded NPs were measured by DLS.

Characterization of Proteinoids and Dox-loaded NPs

The FTIR spectra of the free Dox, proteinoid P(KRHF-PLLA) 20:30 and Dox-loaded NPs are shown in Figure 3. The IR spectrum of free Dox is represented in (A). In this spectrum, a pair of doublets at 3415/3331 cm⁻¹ and at 3023/2926 cm⁻¹ is clearly shown. The first doublet (at 3415/3331 cm⁻¹) can be associated with the H-bonded O-H stretch and N-H stretch (amide I). The second doublet (at 3023/2926 cm⁻¹) corresponds to the C-H stretching of methyl groups and aromatic rings. The peaks at 802 cm⁻¹ and 776 cm⁻¹ are due to the primary amine NH wag and N-H deformation bonds, respectively [41]. The IR spectrum of the proteinoid shown in (B) clearly shows the presence of the groups derived from the amino acids and PLLA, with characteristic peaks at 2934 cm⁻¹ (corresponding to the C-H alkyl stretching band), at 1664 cm⁻¹ (corresponding to the carbonyl C=O vibration, and N-H bend - amide I), at 1537 cm⁻¹ (amide II) and at 1117 cm⁻¹ (corresponding to the stretching of O-O bonds of ester groups). The IR spectrum of the Dox-loaded NPs in (C) shows the proteinoid characteristic peaks, with a small left-shift. In addition, the IR spectrum of Dox-loaded NPs shows a broad peak at 3369 cm⁻¹, a small peak at 2942 cm⁻¹, which can be associated with amide I and C-H stretching coming from Dox, and a broad peak at 802 cm⁻¹. The broadening and shifting of existing peaks in the proteinoid NPs can be associated with the encapsulation of Dox and self-assembly reorganization of proteinoid chains due to NP formation.

The XRD analysis of free Dox along with the proteinoid and freeze-dried Dox-loaded NPs is also shown in Figure 3. Free Dox (D) shows clear peaks in the diffractogram indicating the presence of a crystalline phase in its native form, whereas the proteinoid in (E) shows a typical amorphous pattern, as expected for a random polymerization product. The reduction in number and intensity of the peaks and absence of several peaks in the XRD pattern of Dox-loaded NPs in comparison to the free drug, also indicates the phase transformation of crystalline doxorubicin to amorphous doxorubicin [42].
To verify the encapsulation of Dox within the NPs, characterization of doxorubicin in a solution was performed [43]. The absorbance spectra of free Dox and Dox-loaded NPs containing the same amount of Dox, were measured in physiological pH (7.4) and after proteinoid dissolution at pH 2, as shown in Figure 4. The main absorption peak of Dox occurred at 487 nm at both tested pHs. The main absorption peak at pH 2 was shaped similarly to Dox, however, at pH 7.4 the intensity of the main absorption peak of the Dox-loaded NPs was much lower than the intensity of the main peak of free Dox. This indicates the encapsulation of the drug within the NPs. Additionally, it is seen that at pH 2 the absorption peaks of the Dox-loaded NPs and the free Dox are similar. This fact reveals the release of loaded Dox from the disrupted NPs at this pH.

**Figure 4:** Absorbance of free Dox and Dox-loaded NPs at pH 7.4 and pH 2.

Figure 5 shows a typical SEM image (A) of the dry Dox-loaded NPs. The measured diameter is 51.7 ± 3.1 nm, whereas the hydrodynamic diameter shown in the DLS histogram (B) of the Dox-loaded NPs is 117 ± 31 nm. The difference in diameters is explained by the very hydrophilic character of the proteinoid NPs, causing adsorption of many water molecules on their surface, which are taken into account in the measurement [24].

**Figure 5:** A typical SEM image (A) and DLS histogram (B) of 15% Dox-loaded P(KRHF-PLLA) 20:30 NPs.

**Particle Stability**

The stability of the hollow, and Dox-loaded P(KRHF-PLLA) 20:30 NPs was studied using ζ-potential measurements, shown in Figure 6. The hollow P(KRHF-PLLA) 20:30 NPs were positively charged at acidic (2.83) and neutral (7.4) pH, 2.7 mV and 3.5 mV, respectively, whereas at pH 10.88 the NPs demonstrated a negative charge with -9.0 mV due to the carboxylate groups attached to the surface of the particles. The isoelectric point of the hollow P(KRHF-PLLA) 20:30 NPs was at pH 7.7. The ζ-potential of Dox-loaded P(KRHF-PLLA) 20:30 NPs was positive at pH values ranging between acidic and neutral, similarly to the hollow P(KRHF-PLLA) 20:30 NPs. However, with pH in the range of 5.5 to 7.4, the ζ-potential increased from 5.65 mV at pH 5.5 up to 16.6 mV at pH 7.4. This increase in the ζ-potential can be explained by the protonation of the amine group (pKa 7.6) of the loaded Dox within the NPs [44]. The isoelectric point of the Dox-loaded P(KRHF-PLLA) 20:30 NPs shifted to pH 8.9, and when the pH increased to 10.48, the ζ-potential decreased to -3.29 mV. The decrease in ζ-potential in Dox-loaded NPs is less drastic compared to the hollow P(KRHF-PLLA) 20:30 NPs, probably due to the different self-assembly conditions used for the Dox encapsulation.

**Figure 6:** ζ-potential of the hollow and Dox-loaded P(KRHF-PLLA) 20:30 NPs as function of pH. Each point on the graph is an average of ten performed measurements.

To ensure PEG conjugation to the Dox-loaded P(KRHF-PLLA)
20:30 NPs, ζ-potential of the PEGylated NPs was studied using the same procedure. Figure 7 illustrates that ζ-potential of PEG-Dox-loaded NPs varied around zero in the pH range of 2.8 to 10.15. As shown earlier, the ζ-potential of the Dox-loaded NPs has changed with the pH increase. The decreasing of ζ-potential of the PEG-Dox-loaded NPs to zero (especially in pH 7.4) can be explained by the PEG conjugation to the free amino groups of the Dox-loaded NPs and confirms the successful PEGylation.

NP stability was also determined at different storage conditions: in dispersion at refrigerating conditions over time and after freeze-drying. Proteinoid NP aqueous dispersions (1 mg/mL) kept in a refrigerator at 4 °C for 6 months remained the same size and size distribution, while keeping the drug content constant. Additionally, in order to check particle stability after drying, the particles were freeze-dried and then redispersed in an aqueous phase to their original concentration. The samples' size and size distributions were not affected by this procedure. This provides two types of storing conditions for further applications with the NPs.

**In vitro Drug Release Study**
The in vitro release study of Dox from P(KRHF-PLLA) 20:30 NPs was carried out after NP PEGylation, as described, in various media: PBS, human serum and human whole blood. It should be noted that the NPs size after PEGylation is 154 ± 15 nm. Figure 8 shows the in vitro release profile of Dox from Dox-loaded and from PEGylated Dox-loaded P(KRHF-PLLA) 20:30 NPs.

A variety of factors affect the rate of drug release, such as the polymeric structure, the drug itself, the pH of the medium, etc. The effects of PEGylation of the NPs and the effect of the environment on the release rate of Dox from the NPs were investigated. The release of Dox from non-PEGylated Dox-loaded P(KRHF-PLLA) 20:30 NPs when dispersed in serum and blood was very rapid. However, the rate of Dox release in a PBS dispersion was notably lower. The maximum release of Dox from the NPs was 99% within 24 h, in blood and serum. In PBS, over 24 h, the drug release was only about 40%. The PEGylated NPs have shown a different drug release pattern. The percent of Dox which was released from the PEGylated NPs in human blood reached 87% within 5 h. Contrarily, in PBS and human serum the release of the drug from the NPs was very slow, with a maximum release of 7% over 24 h. This fact can be explained by the assumption that PEGylation of the NPs yields better packaging, with less degradable bonds on the surface of the NPs, which cause the rate of the drug release to be decreased [45]. The high release in blood is attributed to the enzymes which degrade the proteinoid backbone, through hydrolysis of the esters of the PLLA and the peptide bonds [39,46].

In vitro effect of the non-PEGylated and PEGylated Dox-loaded P(KRHF-PLLA) 20:30 NPs on cell proliferation of human A172 glioblastoma, MDA-MB-231 ductal carcinoma and HCT116 colon carcinoma cells was tested using XTT, as described in the experimental part. Figure 9 illustrates the results of the performed XTT experiments of A172 (A), MDA-MB231 (B) and HCT116 (C) cells. Hollow NPs and PEGylated hollow NPs, which served as a control, do not possess any toxicity, showing cell viability levels of 108-119% and 100-103%, respectively, after treatment with a high dose of 0.05 mg/mL. This means that the proteinoid NPs themselves are non-toxic to the body, as expected. However, Dox-loaded NPs, either non-PEGylated or PEGylated, showed low cell viability levels of close to 40%, after treatment with a low dose of 0.01 mg/mL (Dox concentration 1.66µg/mL). Furthermore, this cytotoxic effect is similar to the effect achieved with free Dox at the same concentration. When the concentration of the treating NPs was raised to 0.05 mg/mL (8.3µg/mL) both kinds of NPs were found more toxic, while PEGylated NPs achieved even greater toxicity than that of the free Dox.
Figure 9: Cell viability of human A172 glioblastoma (A), MDA-MB-231 ductal carcinoma (B) and HCT116 colon carcinoma (C) cells 48 h post-treatment measured by XTT assay. Cells were treated with 0.01 and 0.05 mg/mL NPs and an equivalent amount free of Dox. Hollow NPs, PEG NPs and untreated cells served as control. Each bar represents mean ± standard deviations of six separate samples.

**Cytokines Induction Assay**

In order to evaluate the safety profile of the P(KRHF-PLLA) 20:30 NPs as a future drug delivery vehicle, an *ex vivo* cytokine induction study was performed using human Peripheral Blood Mononuclear Cells (PBMCs), to examine the secretion of major inflammatory cytokines. The results are summarized in Table 6. Neither the non-PEGylated Dox-loaded NPs nor the PEGylated ones caused an elevated secretion of both innate and late cytokine response at 2 h and 24 h of treatment with the particles. As a positive control, we used the TLR4 natural ligand and LPS that secreted high levels of both TNF-α and IL-6 after only 2 h of incubation with an increase after 24 h of exposure to the LPS. IL-10 was secreted after 24 h, as expected.

**Table 6:** Effect of Dox-loaded NPs, in presence or absence of bound PEG, on the secretion of TNF-α, IL-10 and IL-6 in human PBMCs 2 h and 24 h of incubation.

| Treatment                  | TNF-α (pg/mL)  | IL-6 (pg/mL)  | IL-10 (pg/mL) |
|----------------------------|----------------|---------------|--------------|
| Negative control (PBS)     | N.D.           | N.D.          | N.D.         |
| Positive control (LPS)     | 6586 ± 1591    | 16697 ± 8875  | 1788 ± 782^b |
|                            | 2480 ± 321^b   | 669 ± 42^b    | N.D.         |
| Dox-loaded NPs             | N.D.           | N.D.          | N.D.         |
| PEG-Dox-loaded NPs         | N.D.           | N.D.          | N.D.         |

^aValues are expressed as means ± standard deviation, N.D. — not detectable; ^bupper limit of quantification.

**Conclusions**

In this study, lysine-based proteinoids were produced via a simple thermal condensation reaction. The proteinoids composed of L-lysine, L-arginine, L-histidine, L-phenylalanine and PLLA, achieved high molecular weights with narrow size distributions and possess optical activity; thus, they may be utilized for drug delivery. The thermal stability of the proteinoids was tested and it increased with the relative ratio of phenylalanine, which was chosen for its rigidity. Hollow and drug-loaded NPs with narrow size distribution were produced using a self-assembly method. NPs with various drug concentrations were synthesized, and the NPs with optimal size, ζ-potential and entrapment efficiency were chosen for further study. It was demonstrated that it is possible to conjugate PEG to the drug-loaded NPs in order to enhance the NP stability and prevent leakage of the drug. The findings confirmed that the PEGylated Dox-loaded NPs are more stable in all environments and the release of the drug occurs only in the blood, as intended.

In future study, the PEGylated Dox-loaded NPs will be tested in vivo using a mouse model to explore the body distribution and half lifetime in the blood. Moreover, conjugation of suitable
targeting agents to the PEGylated Dox-loaded NPs will probably enhance the specific delivery to tumors and increase their affinity. Our intention is to achieve better specificity and targeting to treat cancer better than the currently available Doxil. Additionally, the proteinoid NPs may be used to encapsulate other anti-cancer drugs, such taxol, and even combine drug delivery and tumor tagging by encapsulation of a drug and a dye in one NP.

Acknowledgements
This study was supported by the Israeli Ministry of Commerce and Industry (Kamin Grant). The authors thank Dr. Safra Rudnick-Glick for her assistant with the immunogenic studies.

References
1. Reddy LH, Murthy RS (2004) Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Pap 148: 161-166.
2. Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, et al. (2012) Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol 1: 1-10.
3. Talelli M, Iman M, Varkouhi AK, Rijcken CJF, Schiffelers RM, et al. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials 31: 7797-7804.
4. Hershan DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, et al. (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol 26: 3159-3165.
5. Chatterjee K, Zhang J, Honbo N, Karliner JS (2010) Doxorubicin cardiomyopathy. Cardiology 115: 155-162.
6. Canal F, Sanchis J, Vicent MJ (2011) Polymer-drug conjugates as nano-sized medicines. Curr Opin Biotechnol 22: 894-900.
7. Mauro N, Campora S, Adamo G, Scialabba C, Gherzi G, et al. (2016) Polyaminoacid–doxorubicin prodrug micelles as highly selective therapeutics for targeted cancer therapy. RSC Adv 6: 77256-77266.
8. Shi M, Lu J, Shoichet MS (2009) Organic nanoscale drug carriers coupled with ligands for targeted drug delivery in cancer. J Mater Chem 19: 5485-5498.
9. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE (2009) Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61: 428-437.
10. Varanda LC, Júnior MJ, Beckjúnior W (2011) Magnetic and multifunctional magnetic nanoparticles in nanomedicine: challenges and trends in synthesis and surface engineering for diagnostic and therapy applications. in: A. Laskowsky (Ed.), Biomed Eng Trends Mater Sci InTech 397-424.
11. Soundararajan A, Squamous N, Carcinoma C, Model X (2010) [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Surgery 36: 515-524.
12. (Chezy) Barenholz Y (2012) Doxil® — The first FDA-approved nano-drug: lessons learned. J Control Release 160: 117-134.
13. Zhang L, Chan JM, Gu FX, Rhee J, Wang AZ, et al. (2008) Self-assembled lipid polymer hybrid nanoparticles: a robust drug delivery platform, ACS Nano. 2: 1696-1702.
34. Fox SW, Waehneldt TV (1968) The thermal synthesis of neutral and basic proteinoids, Biochim Biophys Acta - Protein Stucture 160: 246-249.
35. Jiang T, Zhang Z, Zhang Y, Lv H, Zhou J, et al. (2012) Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 33: 9246-9258.
36. Liu BR, Huang Y, Winiarz JG, Chiang HJ, Lee HJ (2011) Intracellular delivery of quantum dots mediated by a histidine- and arginine-rich HR9 cell-penetrating peptide through the direct membrane translocation mechanism Biomaterials 32: 3520-3537.
37. El-Sayed A, Futaki S, Harashima H (2009) Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J 11: 13-22.
38. Futaki S (2005) Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv Drug Deliv Rev 57: 547-558.
39. Xiao L, Wang B, Yang G, Gauthier M (2012) Poly(lactic acid)-based biomaterials: synthesis, modification and applications. in: N Ghista, Dhanjo (Ed.), Biomed Sci Eng Technol, InTech 249-283.
40. Stille JK (1981) Step-growth polymerization. J Chem Educ 58: 862-866.
41. Wu S, Zhao X, Li Y, Du Q, Sun J, et al. (2013) Adsorption properties of doxorubicin hydrochloride onto graphene oxide: Equilibrium, kinetic and thermodynamic studies, Materials 6: 2026-2042.
42. Kalaria DR, Sharma G, Beniwal V, V Ravi Kumar MN (2009) Design of biodegradable nanoparticles for oral delivery of doxorubicin: In vivo pharmacokinetics and toxicity studies in rats. Pharm Res 26: 492-501.
43. Arora HC, Jensen MP, Yuan Y, Wu A, Vogt S, et al. (2012) Nanocarriers enhance doxorubicin uptake in drug-resistant ovarian cancer cells. Cancer Res 72: 769-778.
44. Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, et al. (1999) Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80: 1005-1011.
45. Goudoulas TB (2012) Polymers and biopolymers as drug delivery systems in nanomedicine. Recent Patents Nanomed 2: 52-61.
46. Gow AJ, Duran D, Malcolm S, Ischiropoulos H, Gow J (1996) Effects of peroxynitrite-induced phosphorylation protein modifications and degradation on tyrosine. FEBS Lett 385: 63-66.